Azita Saleki-Gerhardt - 24 May 2021 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, Operations
Signature
Steven L. Scrogham, attorney-in-fact for Azita Saleki-Gerhardt
Issuer symbol
ABBV
Transactions as of
24 May 2021
Net transactions value
-$7,071,803
Form type
4
Filing time
26 May 2021, 17:20:36 UTC
Next filing
22 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Options Exercise $362,452 +12,400 +11% $29.23* 128,684 24 May 2021 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $2,673,778 +74,520 +58% $35.88* 203,204 24 May 2021 Direct
transaction ABBV Common Stock, $0.01 par value Sale $9,051,036 -77,863 -38% $116.24 125,341 24 May 2021 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale $1,056,996 -9,057 -7.2% $116.70 116,284 24 May 2021 Direct F2
holding ABBV Common Stock, $0.01 par value 2,272 24 May 2021 Profit sharing trust F3
holding ABBV Common Stock, $0.01 par value 3,873 24 May 2021 By spouse F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to buy) Options Exercise $0 -12,400 -100% $0.000000* 0 24 May 2021 Common Stock 12,400 $29.23 Direct F5
transaction ABBV Option (Right to buy) Options Exercise $0 -74,520 -100% $0.000000* 0 24 May 2021 Common Stock 74,520 $35.88 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.67 to $116.64 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.67 to $116.79 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Balance in AbbVie Savings program as of May 26, 2021.
F4 The reporting person disclaims beneficial ownership of all securities held by her spouse.
F5 Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

The transactions reported on this Form 4 were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).